Sulfacetamide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Sulfacetamide: From Antibacterial Use to Postinfectious Vasculitis
One-Sentence Summary
Sulfacetamide is a sulfonamide-class antibacterial (folate-synthesis inhibitor); no approved indication record is currently on file for this product. The TxGNN model predicts it may be effective for Postinfectious Vasculitis, but currently 0 clinical trials and 0 publications support this specific direction — the prediction is model-only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file (drug currently not marketed; no approved-indication text available in regulatory data) |
| Predicted New Indication | Postinfectious Vasculitis |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data for sulfacetamide is not available in the evidence pack (flagged as a High-severity data gap). Based on known pharmacology, sulfacetamide is a sulfonamide antibacterial that competitively inhibits para-aminobenzoic acid (PABA), blocking bacterial folate synthesis — a mechanism historically applied to topical/ophthalmic and dermatologic bacterial infections.
Postinfectious vasculitis, however, is an immune-complex-mediated inflammatory disease, not a bacterial infection per se. Per the evidence pack’s own rationale, sulfacetamide’s antibacterial mechanism has no direct pathophysiological connection to vasculitic immune-complex disease — this ranking is driven purely by knowledge-graph embedding similarity, with no supporting clinical trial or literature evidence identified.
Given the absence of any real-world evidence and a mechanistically weak rationale, this specific candidate should be treated as a hypothesis-generating signal only, not a basis for clinical consideration at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA label warnings/contraindications are marked as a Blocking data gap — this prevents the candidate from entering the safety pre-screen (S1) stage until the label is retrieved and parsed.)
Other Predicted Indications Worth Noting
The top-ranked prediction by TxGNN score has the weakest evidentiary support in this evidence pack. Among the 10 candidates evaluated, otitis externa (rank 3) stands out with substantially stronger real-world evidence and a coherent mechanistic rationale (sulfacetamide is a known historical component of trimethoprim-sulfacetamide-polymyxin B ear drops):
| Rank | Disease | Evidence Level | Trials | Literature | Recommendation |
|---|---|---|---|---|---|
| 1 | Postinfectious vasculitis | L5 | 0 | 0 | Hold |
| 3 | Otitis externa | L2 | 0 | 4 (incl. 2 RCTs) | Proceed with Guardrails |
| 10 | Parasitic eyelid infestation | L4 | 0 | 1 | Research Question |
If the goal is to identify the most defensible repurposing candidate for sulfacetamide rather than strictly the top TxGNN-ranked disease, otitis externa merits priority follow-up over postinfectious vasculitis.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (postinfectious vasculitis) is supported only by TxGNN embedding similarity (L5) with zero clinical trials or literature, and the mechanistic link is explicitly assessed as weak/absent in the evidence pack itself. Additionally, a Blocking data gap (missing TFDA label warnings/contraindications) prevents even a preliminary safety screen.
To proceed, the following is needed:
- Retrieve and parse TFDA label (warnings/contraindications) — currently Blocking (DG001)
- Obtain confirmed mechanism-of-action data via DrugBank API (DG002)
- If pursuing repurposing for sulfacetamide, redirect evaluation toward otitis externa (rank 3), which has an L2 evidence base including two RCTs on trimethoprim-sulfacetamide-polymyxin B ear drops
- If postinfectious vasculitis is still of interest, commission a targeted literature/mechanism review before any further evaluation stage
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.